A Dravet medicine trial will measure changes in four areas of thinking and behavior
Stoke Therapeutics (STOK) completed a meeting with the FDA to align on the planned U.S. NDA for zorevunersen, an investigational treatment for Dravet syndrome. The Phase 3 EMPEROR study will assess changes in cognition and behavior using four Vineland-3 subdomains. Data submissions are expected in the first half of 2027, with a Phase 3 readout anticipated in Q3 2027. The company plans to complete the NDA submission in the second half of 2027.
How this was made
The 30-second read
Why it matters
The FDA meeting outcome reduces regulatory risk and clarifies the trial's secondary endpoint assessment, which could positively affect the stock.
Market read
New FDA alignment may prompt short‑term buying interest in STOK.
What to watch
Potential competition from other Dravet therapies and execution risk of intrathecal delivery.
Background
Stoke Therapeutics is developing zorevunersen, an antisense oligonucleotide for Dravet syndrome, with orphan and breakthrough designations.
Ticker impact
Stoke Therapeutics announced FDA alignment on its Phase 3 EMPEROR trial design and plans staged data submissions for zorevunersen.
potential upside as market prices in favorable regulatory alignment
The FDA meeting outcome is new material information that reduces regulatory uncertainty for the drug.
Market effects
May lift sentiment for the rare‑disease biotech sector.
US biotech stocks could see modest gains.
Limited to investors tracking FDA‑regulated drug pipelines.
Counterpoint
If the trial fails to meet endpoints, the earlier FDA alignment may not translate into price gains.
Key entities
- companyStoke Therapeutics
Biotech firm developing zorevunersen for Dravet syndrome.
- partnerBiogen
Strategic collaborator with Stoke on zorevunersen commercialization.
